ArticleNuclear medicine communications2019
An electronic technetium-99m-diethylenetriaminepentaacetic acid glomerular filtration rate spreadsheet with novel embedded quality assurance features.
Article in Nuclear medicine communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCritical clinical decisions are made on the basis of the glomerular filtration rate (GFR) measured using technetium-99m-diethylenetriaminepentaacetic acid (DTPA) administration, followed by multiple time-point plasma sampling. As GFR studies rely on few data points and produce a single result, they are prone to technical errors that may remain inconspicuous.
objectiveWe describe a data analysis worksheet that provides real-time quality control (QC) indicators and evaluate our initial clinical experience.
methodsTwo hundred and forty-six consecutive GFR studies carried out at our clinics were included. Our protocol used plasma samples at 2, 3, and 4 h after injection of technetium-99m-DTPA. Duplicate plasma samples, background samples, and aliquots of an activity dilution standard were counted. Times were logged for injection and dilution standard preparation, blood sampling, and counting. Data were entered into a custom GFR analysis spreadsheet that flagged QC in real time at warning and error levels, including QC of the expected ratio between dilution standard counts-activity ratio (CARs) measurements, which was newly introduced to our clinic. The prevalence of QC events was analyzed in three phases: baseline, training, and evaluation (n=31, 69, and 146, respectively).
resultsFrom the baseline and training phases (n=100), CAR reference values were determined for each of two sites. In the absence of the CAR QC indicator, errors were present in 5/31 (16%) examinations, but with QC indication decreased to 7/146 (5%) (P<0.05), suggesting that the real-time QC information guided the technologists to ensure proper standard preparation and sample handling, as intended. Improvements in other QC measures were also noted, resulting in an overall error rate reduction from 23 to 8%.
conclusionReal-time analysis of redundant information as a component of the GFR worksheet ensures quality results, but training of technologists and interpreting physicians is essential for optimal utilization of these QC indicators.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.